WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Enliven Therapeutics earnings were -$105.9M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest ELVN earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$32.5M, up 37.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ELVN reported annual earnings of -$103.7M, with 16.5% growth.

ELVN earnings history

Current Revenue
$0.0
Current Earnings
-$105.9M
Current Profit Margin
0%

ELVN Return on Equity

Current Company
-18.5%
Current Industry
-13.6%
Current Market
32.8%
ELVN's Return on Equity (-18.5%)... subscribe to Premium to read more.
High Return on Equity Performance

ELVN Return on Assets

Current Company
-18.1%
Current Industry
-10.2%
ELVN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ELVN announces earnings.

ELVN Return on Capital Employed

Current Company
-11.82%
Current Industry
-6.7%
ELVN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ELVN vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ELVN-$105.40M-$105.93MN/A-$1.67
RLAY-$283.83M-$286.04MN/A-$1.56
LEGN$11.24M-$91.69MN/A-$0.50
DYN-$502.02M-$519.41MN/A-$3.30
MANEN/AN/AN/AN/A
View Top Biotech Stocks

Enliven Therapeutics Earnings Reports & History FAQ

What were Enliven Therapeutics's earnings last quarter?

On ELVN's earnings call on Aug 12, 2026, Enliven Therapeutics (NASDAQ: ELVN) reported Q2 2026 earnings per share (EPS) of -$0.49, up 0% year over year. Total ELVN earnings for the quarter were -$32.49 million. In the same quarter last year, Enliven Therapeutics's earnings per share (EPS) was -$0.49.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.

Is Enliven Therapeutics profitable or losing money?

As of the last Enliven Therapeutics earnings report, Enliven Therapeutics is currently losing money. Enliven Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$105.93 million, a 5.7% increase year over year.

What was ELVN's earnings growth in the past year?

As of Enliven Therapeutics's earnings date in Aug 12, 2026, Enliven Therapeutics's earnings has grown year over year. ELVN earnings in the past year totalled -$105.93 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.